

HIC1 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP14127b**Specification**

HIC1 Antibody (C-term) Blocking peptide - Product InformationPrimary Accession [Q14526](#)**HIC1 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 3090**Other Names**

Hypermethylated in cancer 1 protein, Hic-1, Zinc finger and BTB domain-containing protein 29, HIC1, ZBTB29

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP14127b was selected from the C-term region of HIC1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

HIC1 Antibody (C-term) Blocking peptide - Protein Information**Name** HIC1**Synonyms** ZBTB29**Function**

Transcriptional repressor (PubMed: [12052894](http://www.uniprot.org/citations/12052894), PubMed: [15231840](http://www.uniprot.org/citations/15231840)). Recognizes and binds to the consensus sequence '5-[CG]NG[CG]GGGCA[CA]CC-3' (PubMed: [15231840](http://www.uniprot.org/citations/15231840)). May act as a tumor suppressor (PubMed: [20154726](http://www.uniprot.org/citations/20154726)). Involved in development of head, face, limbs and ventral body wall (By similarity). Involved in down-regulation of SIRT1 and thereby is involved in regulation of p53/TP53- dependent apoptotic DNA-damage responses (PubMed: [16269335](http://www.uniprot.org/citations/16269335)). The specific target gene promoter association seems to be

depend on corepressors, such as CTBP1 or CTBP2 and MTA1 (PubMed:12052894, PubMed:20547755). In cooperation with MTA1 (indicative for an association with the NuRD complex) represses transcription from CCND1/cyclin-D1 and CDKN1C/p57Kip2 specifically in quiescent cells (PubMed:20547755). Involved in regulation of the Wnt signaling pathway probably by association with TCF7L2 and preventing TCF7L2 and CTNNB1 association with promoters of TCF-responsive genes (PubMed:16724116). Seems to repress transcription from E2F1 and ATOH1 which involves ARID1A, indicative for the participation of a distinct SWI/SNF-type chromatin-remodeling complex (PubMed:18347096, PubMed:19486893). Probably represses transcription of ACKR3, FGFBP1 and EFNA1 (PubMed:16690027, PubMed:19525223, PubMed:20154726).

Cellular Location

Nucleus.

Tissue Location

Ubiquitously expressed with highest levels found in lung, colon, prostate, thymus, testis and ovary. Expression is absent or decreased in many tumor cells

HIC1 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

HIC1 Antibody (C-term) Blocking peptide - Images

HIC1 Antibody (C-term) Blocking peptide - Background

This gene functions as a growth regulatory and tumorrepressor gene. Hypermethylation or deletion of the region of thisgene have been associated with tumors and the contiguous-genesyndrome, Miller-Dieker syndrome. Alternative splicing of this generesults in multiple transcript variants.

HIC1 Antibody (C-term) Blocking peptide - References

Pehlivan, S., et al. Cancer Genet. Cytogenet. 201(2):128-132(2010)Van Rechem, C., et al. Mol. Cell. Biol. 30(16):4045-4059(2010)Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :Zhang, B., et al. Mol. Endocrinol. 23(12):2075-2085(2009)Tseng, R.C., et al. Neoplasia 11(8):763-770(2009)